| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
ODN D-SL-03 targets human Toll-like receptor 9 (TLR9). It is a class C CpG oligonucleotide that effectively stimulates peripheral blood mononuclear cells (PBMCs) to produce high levels of IFN-alpha and activates human B cells, NK cells, and mononuclear cells.
|
|---|---|
| ln Vitro |
At a dose of 0.19 μg/mL, ODN D-SL03 (0-3 μg/mL; 36 hours) significantly increases IFN-α production in PBMC [1]. B, NK, T, and monocytes are among the immune cells that are activated by ODN D-SL03 (3 μg/mL; 18 or 36 hours) [1].
At 0.19 microg/mL, ODN D-SL-03 significantly increases IFN-alpha production in human PBMCs. At 3 microg/mL, it activates B, NK, T, and monocytes and upregulates CD80, CD86, and HLA-DR expression on human PBMC subsets, contributing to its antitumor immune activity. |
| ln Vivo |
ODN D-SL03 (25 μg per animal; peritumoral injection) can effectively decrease tumor growth [1].
In female Balb/c mice bearing EMT6 tumors, peritumoral injection of ODN D-SL-03 (25 microg per mouse, 6 injections, 1 day apart) effectively decreases tumor growth, demonstrating in vivo antitumor efficacy via activation of innate and adaptive immune responses. |
| Enzyme Assay |
Not applicable. As a TLR9 agonist oligonucleotide, its activity is assessed in cellular systems. Engagement is measured via TLR9-mediated signaling and subsequent cytokine production, not by classical cell-free receptor-ligand binding.
|
| Cell Assay |
Human PBMCs are isolated and seeded in 96-well plates. ODN D-SL-03 (0-3 microg/mL) is added for 18-36 hours. IFN-alpha production is measured by ELISA. B, NK, and T cell activation is assessed by flow cytometry for CD80, CD86, and HLA-DR expression. Apoptosis is measured by Annexin V/PI staining.
|
| Animal Protocol |
Animal/Disease Models: Female balb/c (Bagg ALBino) mouse (6-8 weeks; inoculated with 5×105 EMT6 cells) [1]
Doses: 25 μg per mouse Route of Administration: 6 peritumoral injections, 1 day apart, lasting 0- 100-day Experimental Results: Significant inhibition of tumor growth. EMT6 tumor cells are inoculated into female Balb/c mice. ODN D-SL-03 (25 microg/mouse) is administered via peritumoral injection on days 0, 1, 2, 3, 4, and 5 (6 injections total). Tumor volume is measured with calipers. Blood and tumor tissues are collected for immune cell infiltration analysis and cytokine profiling. |
| ADME/Pharmacokinetics |
PK data are limited. ODN D-SL-03 is formulated in H2O (≥20 mg/mL) and administered via peritumoral injection. Storage: powder at -20degC for 3 years; in solvent at -80degC for 6 months. The phosphorothioate-modified backbone provides resistance to nuclease degradation.
|
| Toxicity/Toxicokinetics |
Standard safety precautions for oligonucleotides apply. ODN D-SL-03 is for research use only, not for human therapy. Avoid inhalation and contact. Use PPE in a well-ventilated area. The compound may cause immunostimulatory adverse effects at high doses.
|
| References | |
| Additional Infomation |
This is a research-grade TLR9 agonist. ODN D-SL-03 is used as a vaccine adjuvant and cancer immunotherapeutic agent in preclinical studies. Sequence: 5‘-tcgcgaacgttcgccgcgttcgaacgcgg-3'. It is also known to inhibit tumor growth.
|
| Molecular Weight |
0
|
|---|---|
| CAS # |
1198621-85-0
|
| Appearance |
Off-white to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 20 mg/mL (~2.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
